NCEL News

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

NewcelX CEO Issues Letter to Shareholders

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.